Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Patricia Marino (), Rajae Touzani (), Lionel Perrier, Etienne Rouleau (), Dede Sika Kossi, Zou Zhaomin, Nathanaël Charrier, Nicolas Goardon, Claude Preudhomme (), Isabelle Durand-Zaleski, Isabelle Borget, Sandrine Baffert (), Lucie Coppin, Julie Leclerc and Marie-Francoise Odou
Additional contact information
Patricia Marino: SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale
Rajae Touzani: SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale - IRD - Institut de Recherche pour le Développement - AMU - Aix Marseille Université - INSERM - Institut National de la Santé et de la Recherche Médicale
Etienne Rouleau: Département de biologie et pathologie médicales [Gustave Roussy] - IGR - Institut Gustave Roussy
Dede Sika Kossi: Fondation Ophtalmologique Adolphe de Rothschild [Paris]
Zou Zhaomin: Etudes et Recherche en économie de la santé - SBE - Service de biostatistique et d'épidémiologie - Direction de la recherche clinique [Gustave Roussy] - IGR - Institut Gustave Roussy
Nathanaël Charrier: URC Eco - Unité de recherche clinique en économie de la santé d'Ile-de-France - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôtel-Dieu
Nicolas Goardon: UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen] - NU - Normandie Université - UNICANCER - TCBN - Tumorothèque de Caen Basse-Normandie
Claude Preudhomme: Centre de Biologie et de Pathologie - Laboratoire d'Hématologie [CHRU Lille] - CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille], JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 - Université Lille Nord de France (COMUE) - INSERM - Institut National de la Santé et de la Recherche Médicale - Université de Lille
Isabelle Durand-Zaleski: URC Eco - Unité de recherche clinique en économie de la santé d'Ile-de-France - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôtel-Dieu
Isabelle Borget: Etudes et Recherche en économie de la santé - SBE - Service de biostatistique et d'épidémiologie - Direction de la recherche clinique [Gustave Roussy] - IGR - Institut Gustave Roussy
Sandrine Baffert: Fondation Ophtalmologique Adolphe de Rothschild [Paris]
Lucie Coppin: JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 - Université Lille Nord de France (COMUE) - INSERM - Institut National de la Santé et de la Recherche Médicale - Université de Lille
Julie Leclerc: JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 - Université Lille Nord de France (COMUE) - INSERM - Institut National de la Santé et de la Recherche Médicale - Université de Lille
Marie-Francoise Odou: LIRIC - Lille Inflammation Research International Center - U 995 - Institut Pasteur de Lille - Pasteur Network (Réseau International des Instituts Pasteur) - INSERM - Institut National de la Santé et de la Recherche Médicale - Université de Lille - CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]

Post-Print from HAL

Abstract: It is currently unclear if next-generation sequencing (NGS) technologies can be implemented in the diagnosis setting at an affordable cost. The aim of this study was to measure the total cost of performing NGS in clinical practice in France, in both germline and somatic cancer genetics.The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. In addition, we used a top-down methodology for specific post-sequencing steps including bioinformatics, technical validation, and biological validation. Additional non-specific costs were also included. Costs were detailed per step of the process (from the pre-analytical phase to delivery of results), and per cost driver (consumables, staff, equipment, maintenance, overheads). Sensitivity analyses were performed.The mean total cost of NGS for targeted gene panels was estimated to 607€ (±207) in somatic genetics and 550€ (±140) in germline oncogenetic analysis. Consumables were the highest cost driver of the sequencing process. The sensitivity analysis showed that a 25% reduction of consumables resulted in a 15% decrease in total NGS cost in somatic genetics, and 13% in germline analysis. Additional costs accounted for 30-32% of the total NGS costs.Beyond cost assessment considerations, the diffusion of NGS technologies will raise questions about their efficiency when compared to more targeted approaches, and their added value in a context of routine diagnosis.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in European Journal of Human Genetics, 2018, 26 (3), pp. 314-323. ⟨10.1038/s41431-017-0081-3⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-01703194

DOI: 10.1038/s41431-017-0081-3

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().